Emmanouil Rizos

TL;DR: The findings indicate that BDNF levels at the onset of schizophrenia may reflect associated pathophysiological processes as well as the severity of positive and negative psychotic symptoms.

TL;DR: The findings may indicate a differential effect of olanzapine on BDNF levels compared to haloperidol, risperidone, and amisulpride, and the possible differential effects of treatment with typical and atypical antipsychotics on serumBDNF levels in the same group of patients.

TL;DR: The COVID-19 pandemic has had serious implications on the lives of medical students including their psychological well-being and the impact on their academic trajectories, and the urgency for rapid and novel adaptations to the new circumstances has functioned as a springboard for remarkable innovations in medical education, including the promotion of a more "evidence-based" approach as discussed by the authors.

TL;DR: This narrative review seeks to present a comprehensive overview of current understanding of clinical features, risk factors, and pathophysiological processes of neurological ‘long-COVID’ sequelae, and proposes diagnostic and therapeutic algorithms that may aid in the prompt recognition and management of underlying causes of neurological symptoms that persist beyond the resolution of acute COVID-19.

TL;DR: It is found that hippocampal volume (HV) was decreased in FEP patients, and low serum BDNF levels are associated with reduction in HV at the onset of schizophrenia, which may further support the theory of a neuroprogressive-neurotoxic reaction associated with the start of psychosis.